International Journal of Research in AYUSH and Pharmaceutical Sciences

Research Article

A CONTROLLED EVALUATION OF EFFECT OF *MADHUMEHA NASHINI GUTIKA* IN *STHULA PRAMEHA* WITH REFERENCE TO TYPE II DIABETES MELLITUS

Prerna R Masatkar^{1*}, Raman R Ghungralekar²

*¹Associate Professor, Department of Kayachikitsa, Government Ayurved College, Nagpur, Maharashtra, India. ²Dean, GAC, Jalgaon, Maharashtra.

ARTICLE INFO

Article history:

Received: 26-05-2023 Revised: 12-06-2023 Accepted: 30-06-2023

Keywords:
Apatarpan,
Bahudrava
shleshma,
Bahuabadhdha
meda, Sthula
pramehi, Diabetes
mellitus.

ABSTRACT

Ayurveda the science of life is eternal which deals with the healthy as well as diseased individual. Prameha described in Ayurvedic literature is very much similar to the diabetes mellitus of modern medicine with the abrupt change in the modern life style the prevalence of all types of diabetes is on the rise in the world's population. *Charak* has mentioned that Sthula Pramehi where Kleda Meda and Kapha are vitiated Apatarpan should be given. Properties of Madhumeha Nashini Gutika prompted us to select the drug in the management of Sthula Prameha. Methodology- The present study is open labelled randomized control trail. The study duration was 12 weeks from the day of recruitment of patients. Group A (trail group) comprised of 20 patients to whom Madhumeha Nashini Gutika 500mg BID was given while in Group B (control group) also comprised of 20 patients treated with tablet metformin in a dose of 500mg BID after food along with drinking water. All the patients were strictly examined according to the criteria of diagnosis having BMI more than 25 were included in the study randomly. Analysis- The outcome measures of this study was to evaluate the effect of therapy on the symptoms of Prameha in terms of % of relief, on physical characters of body such as wt in kg and BMI and biochemical markers such as blood sugar level, HbA1c before and after treatment in both the groups. **Results and Conclusion-** Overall % of relief in treated group was 73.61%which was more than control group where it was found to be 58.59%. Reduction in weight of patients of treated group was highly significant as t was 8.09 (p<0.001) as compared to control group where t was 0.2525 (p>0.1). Highly significant reduction in BMI values was also noted in treated group as t was 8.83 (p<0.001) as compared to control group where t=0.1625 (p>0.1) so we came at the conclusion that Madhumeha Nashini Gutika might be working on Bahudrava Shleshma and Bahu Abadhdha Meda dhatu.

INTRODUCTION

Ayurveda being *Upaveda* of *Atharv Veda* deals with the prevention as well as treatment of the disease. Description of the disease *Prameha* has been found since *Vedic* era. The disease was known as *Asrava*.^[1] The first incidence of *Prameha* was seen after the consumption of *Havish* special fond offered at the *Yagyna*, organized by Daksha Prajapati. ^[2]

Quick Response Code

Access this article online

https://doi.org/10.47070/ijraps.v7i6.146

Published by Mahadev Publications (Regd.) publication licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)

The prefix 'Pra' means- 'Prakarshena' suggested excessive urination with increase in quantity and frequency. The verb 'Mih' means 'Sinchane' i.e., to flow, the another meaning is 'Ksharane' suggested loss of vital Dhatus through urine. Prameha is defined as "Prakarshen Mehati Prabhutam Varam Varamva Iti Prameha". [3] The cardinal symptom of Prameha is 'Prabhuta Mutrata' and 'Avil Mutrata'. [4] Charaka has described 20 types of Prameha depending upon Doshik predominance. [5] Over indulgence in Hetus leads to vitiation of all the three Doshas especially Kapha Dosha Dushyas predominantly Meda and Mamsa along with Rakta, Shukra, Ambu, Vasa, Lasika, Majja, Rasa, and finally Ojas are involved in

pathogenesis of *Prameha. Kaphaj* and *Pittaj Prameha* if left untreated end up in *Madhumeha* which explains us chronicity of the disease.[6] Diabetes mellitus a syndrome defined as disturbance of intermediary metabolism manifestating a chronic sustained hyperglycemia primary due to either an absolute or relative lack of insulin.[7] There is probably not a single tissue in the body that escapes the effect of high blood sugar of diabetes. We need insulin to convert glucose to energy. As previously believed diabetes is not always due to lack of insulin but is results due to ineffective insulin which we call insulin resistance. As overweight or obesity is the main cause of insulin resistance losing weight certainly helps in reducing the blood sugar level and it can prevent diabetes in vulnerable persons. Indians are more prone to diabetes than almost any other population in the world. Due to increase in following western dietary habits, unsuited for our environs, adopting sedentary life style and exposed to psychosocial stress. Diabetes mellitus is the leading cause of end stage renal failure, non-traumatic amputations, responsible for 30% of preventable diabetic blindness and a leading cause of cardio vascular mortality. Diabetes mellitus impose a tremendous burden on individual and health care system. The concentration of glycosulated haemoglobin is taken as an index of protein glycosylation. It reflects the state of glycemia over the preceding 2-3 months. Obesity and overeating plays an important role in type II DM, and there is a co relation between the disease and the increasing age. Two metabolite defects characterize type II DM. A) a derangement in insulin secretion that is delayed or insufficient relative to the glucose load B) an inability to the peripheral tissues to respond to insulin action. Prameha is Mahagada which is Asadhya may be manifested in two ways. They are termed as 'Sahaja' i.e., Bijadoshokrit and 'Doshajnya' i.e., Apathya nimittaja. Sahaj pramehi are Krish and have dominantly Ruksha properties, these patients have the habit of taking less amount of food (Alpashi), and are thirsty (*Pipasu*). While *Apathya* Nimmittaja Prameha is caused by Ahitkar Ahara and Vihara, these patients are Sthula and have dominance of Snigdha properties also these patients are indulged in sedentary work and excessive sleeping.[7] For the manifestation of the disease three vital factors are responsible such as 'Nidana' 'Dosha' 'Dushya'. Collaboration of these three factors is termed as 'Vicar-Vighatakar-Bhava-abhava'.[8] This Vighatkar Bhava Anubandhitva-Nanubandhitva will manifest in disease or healthy (non-disease) condition of a person. Baliyansi Nidanadi bhava will cause Balvan Vyadhi. Anubandhi means Anukula

when *Hetus* with same properties as that of *Dosha* are indulged vitiate *Dosha* after that vitiates *Dushyas*, thus *Sammurchana* between *Dosha* and *Dushyas* manifest in *Vyadhi*. *Nidana* of *Prameha* are classified into two groups: a) *Samanya Nidana* b) *Vishesh Nidan*.

Samanya Nidana:-Bahudraya Shleshma is the main causative factor in the pathogenesis of *Prameha*.[9] Hence Hetus which predominantly vitiates Khapa Dosha are described. The individuals who have the habit of excessive eating irrespective of their Agni, Satmya, Asatmya are prone to Prameha. Food stuffs having Guru, Sheeta Sandra Sthira, Pichchila guna, Madhura, Amla, Lavana rasa having Dosha Anubandhitva to Kapha, vitiates Kapha and Medo dhatu, the main key factor. So also Dadhi Guda Ikshu Vikara, Anup Audaka, Gramya mamsa, Dugdha Payasa and its *Vikara*, *Surapan* are also responsible. [10] The main Apathyakara Viharaj hetu is Swapnasukha. Persons indulged in luxurious sitting, not performing any hard work, Diwaswapa, Atinidra, are prone to Prameha. Any causative factor Shleshma Medo Mutra Sanjanana is responsible for vitiation of Kapha dosha along with Medo and Mamsa dhatu. Above Nidana cause *Apathva Nimittaia Prameha* which occurs latter in life. [11] Acharya Bhela has termed it as Swakritja.

Vishesh Nidana: Hetus responsible for vitiation of specific Doshas and finally manifest in Doshaj type of Prameha. Kapha Prakopjanaka Ahara Vihar vitiates specifically Kapha dosha which is Bahudrava in characteristics. Thus excessive amount of *Kaph Dosha* having Drava gunatva circulates in the body and combines with Medo dhatu which is Bahu Abadhdha in nature both in tern get mixed with Mamsa and *Sharirstha Kleda.* This collaboration further increases Mamsa and Kleda with defective quality. Kleda is waste metabolite which is formed due to Skukshm Pachana and Sthula Pachana. In Prameha due to Sharira Shithilya and Dhatwagni Mandya Sukshma Keda Pachan is increased. This vitiated Kleda along with *Mutra* is carried towards *Basti* through Mutravaha strotas. As function of Mutra is to excret Kleda, results in Prabhuta Avil Mutrata. [12] Sushruta explained that Aparipakva dosha along with Medo dhatu comes near Basti Mukha and causes various types of *Prameha. Vaabhata* is of the opinion that the predominance of the *Vata*, *Pitta*, *Kapha* in three types of Prameha is only due to relative predominance of three *Doshas*. The primary cause is said to be vitiated Kapha along with respective Dushyas. Kaphaj Prameha is Sadhya because of Samkriyatvat. Pittaja Prameha is Yapya i.e., it can be controlled with treatment. The reason behind this being Vishamkriyatvata. Vataj Prameha is Asadhya because of Mahatyayatvata and Virrodhdhopkramatvata.

Sahaj Prameha is also Asadhya. [13] All Prameha converted to Madhumeha are Asadhya. [14] Kaphaj and Pittaj Prameha presented with very few Purvaroopa and Vataj Prameha without prodromal symptoms are Asadhya. [15] If Pidakas are manifested in Prameha it is Asadhya. Prameha with Upadrava, Arisht lakshana and Atiprabhut Mutrata is Asadhya. [16]

Management of Prameha: Ahara Vihara and Aushadhi dravayas play pivotal role to relieve the patient from abnormal imbalance in Dhatu. In Prameha pathogenesis three Doshas, ten Dushyas along with Agni is also hampered, this makes the disease difficult to treat. The rationale for the treatment is as follows: 1) To eliminate vitiated Doshas especially Bahu Drava Shleshma. 2) To counter vitiated Dhatu, the chief being Meda and Mansa. 3) To control loss of major Dhatus and Oja via urine. 4) To control *Dhatu Shaithilya.* Replenishment of lost *Dhatus* and *Ojas* via urine 6) To maintain good quality of life. 7) To enhance production of *Dhatu* with proper strength. *Charaka* has classified patients of Prameha as Sthula Prameha and Krish Prameha. [17] Charaka has explained Brihan Chitiktsa for Krishaprameha by which increased Vata dosha can be alleviated as well as vital elements of body such as Dhatu will be increased. Vaabhata stated that Shamana should be given to Krish Pramehi. [18] He has told several Shamana Yogas for the treatment of Prameha. Most of these drugs have action as Santarpan.

Chikitsa of Sthula Prameha: Charaka has enlighten that Shodhana in the form of Vamana and Virechana should be given to those patients who have Balvan Dosha and Sharira. [19] However Sthula Prameha patients having Alpa or Madhyam type of Sharira and Dosha Bala, Langhan and Langhan-Pachan mode of treatment should be used.

Role of *Apatarpana* In Sthula *Madhumeha*: In *Shtula Prameha Apatarpan Chikitsa* is given in such as that *Agni* of patient should not be increased. To maintain this equilibrium of *Dosha Dushya* and *Agni Guru Apatarpan* concept of management of *Sthaulya*

as stated by *Vagbhata* in *Ashtangasamgraha*^[20] should be advised to control excessive *Medadhatu*. In *Sthula Pramehi Shushruta* has explained importance of *Shilajeeta*.

AIMS AND OBJECTIVES

Prameha is Santarpanjanya Vyadhi managed with Apatarpana. In Sthula Pramehi Bahudrava Kapha, Bahiabadhdha Meda and Kleda are involved. Thus the concept of Apatarpana is applied here. 1) To evaluate the effect of Madhumeha Nashini Gutika on Prameha lakshana. 2) To evaluate blood sugar level lowering capacity of Madhumeha Nashini Gutika in patients of prameha. 3) To find out and or to propose the mechanism of action of Madhumeha Nashini Gitika. 4) To clinically corelate Prameha and diabetes mellitus as also modalities of treatment.

MATERIALS AND METHODS

Design of Study: Open randomised control study. We planned to study 40 pts of *Madhumeha* in which 20 pts were in study group (*Madhumeha Nashini Gutika* was given), another 20 pts included in control group (metformin was given) with follow up of 12 weeks. Clinical evaluation was done to evaluate symptomatic improvement after every 2 weeks and blood sugar and urine sugar were investigated after 4 weeks. HbA1c and other investigations were carried out after 12 weeks.

Criteria of Selection: Patients with classic symptoms of *Prameha*, BMI more than 25 were selected. 1) Fasting plasma glucose in between110mg%-250mg% 2) Post prandial plasma glucose in between 140mg%-450mg% 3) Type II DM patients 4) Uncomplicated 5) Both sexes 6) Age between 40-65 yrs old.

Criteria of Rejection: 1) Blood glucose level (pp)>450mg%. 2) Age below 45yrs and above 65yrs. 3) Pregnancy and lactating mothers. 4) All patients with acute complication like hyperglycemic coma, ketoacidosis and infection like gangrene were also not considered.

Groups of Management	Treatment group	Control group		
Drug	Madhumeha Nashini Gutika	Metformin		
Dose and Duration	500mg BID	500mg BID		
Anupana	Lukewarm water	Lukewarm water		
Duration	12 weeks	12 weeks		

Investigations: CBC, ESR, LFT, RFT, lipid profile, HbA1c values were estimated before and after completion of treatment.

Criteria of Assessment: Over all relief was checked on objective and subjective measures.

Subjective Parameter- Following 10 symptoms of Prameha were graded from 0-3 (as shown in table 8).

Prerna R Masatkar. Effect of Madhumeha Nashini Gutika in Sthula Prameha wrt Type II Diabetes Mellitus

Values were noted before and after treatment and evaluated in terms of % of relief. 1. Daurbalya 2. Kshudhavriddhi 3. Kshudhamandya 4. Pipasa atipravritti 5. Ayasen Shwasa 6. Prabhut-Mutrata 7. Nakta-Mutruta 8. Pindikodvesthtena 9. Swedati Pravritti 10. Hast-padtalaDaha.

Objective Parameter- Blood sugar level 1. Fasting and 2. Post prandial 3. Average blood sugar level 4. Urine sugar level 5. HbA1c 6. Weight 7. BMI. All these values were noted before and after treatment.

Assessment of Tolerability: Effects of the drugs were observed on patients along with side effects, unwanted effects and complication.

Analysis: The students "t" test was applied to the data. Thus statistical analysis was done to find out significant improvement. Statistical analysis was done on demographic and other details were obtained from case records and were described in tabulated form.

Drug Under Trial: The drug is defined as the one which acts with the help of its qualities. ^[21] In *Sthula pramehi* the drug is given having opposite properties of vitiated *Kapha, Meda* and *Kleda*. Drug used in this study is described by Acharya Yadavji Trikamji named "*Madhumeha Nashini Gutika*". This drug has *Trivanga bhasma-*1 part, *Gudmara churna-*3 part, *Nimba churna-*3part and *Shilajatu-*6part. ^[22]

OBSERVATION AND RESULTS

Table 1: Showing Age Wise Distribution of 40 Patients of *Prameha*

C No	Ago Croup	Treated	Treated Group		roup	Total No.	Percentage	
S. No	Age Group	No. of pts.	%	No. of pts.	%	of Pts.	reftentage	
1)	Tarunavastha (17-40 yrs)	1	5%	3	15%	4	10%	
2)	Praudhavastha (41-60 yrs)	19	95%	16	80%	35	87. 5%	
3)	Vriddhavastha (Above 60 yrs)	0	0%	1	5%	1	2. 5%	

Table 2: Showing Sex Wise Distribution of 40 Patients of Prameha

S.	Sex Group	Treated Group		Control G	roup	Total No.	Dongontago	
No		No. Of pts.	%	No. of pts.	%	of Pts.	Percentage	
1)	Male	6	30%	13	65%	19	47. 5%	
2)	Female			7	35%	21	52. 5%	

Table 3: Showing Dominant Rasa in Aahar of 40 Patients of Prameha

	rabic 51 c			a milanar or	101441011		101
S. No	Dominant <i>Rasa</i> In <i>Aahar</i>	Treated Group		Control (Group	Total No.	Donaontogo
3. NU		No. of pts.	%	No. of pts.	%	of Pts.	Percentage
1)	Madhur	20	100%	20	100%	40	100%
2)	Amla	15	75%	10	50%	25	62.5%
3)	Lavan	18	90%	17	85%	35	87.5%
4)	Katu	10	50%	8	40%	18	45%
5)	Tikta	02	10%	2	10%	4	10%
6)	Kashaya	01	5%	02	10%	03	7.5%

Table 4: Showing Dietic Habits of 40 Patients of Prameha

	8											
S. NO.	Dietic habit	Treated Group		Control	Group	Total	Dorgontago					
		No. of pts.	%	No. of pts.	%	No. of Pts.	Percentage					
1)	Samashana	4	20%	3	15%	7	17.5%					
2)	Vishamashana	16	80%	17	85%	33	82. 5%					
3)	Mixed	14	70%	14	70%	28	70%					

Website: http://ijraps.in

IJRAPS, 2023:7(6):14-23

Table 5: Showing Type of Work Done By 40 Patients of Prameha

S.	Type of work	Treated Group		Control	Group	Total No.	Percentage	
No.	Type of work	No. of pts.	%	No. of pts.	%	of Pts.	rereentage	
1)	Manual	03	15%	04	20%	7	17.5%	
2)	Sitting/Sedentary	12	60%	14	70%	26	65%	
3)	Standing	03	15%	01	5%	04	10%	
4)	Labour	02	10%	01	5%	03	7.5%	

Table 6: Showing Doshaj Prakriti in 40 Patients of Prameha

S.	Darah ad Darahadid	Treated Group		Control (Group	Total No.	Dongontago	
No.	Doshaj Prakriti	No. of pts.	%	No. of pts.	%	of Pts.	Percentage	
1)	Vata-Pittaj	07	35%	04	20%	11	27. 5%	
2)	Pitta-Kaphaj	04	20%	06	30%	10	25%	
3)	Kapha-Vataj	09	45%	10	50%	19	47. 5%	

Figure 1: Showing Incidence of Main *Vyadhi Ghatak* Involved in 40 Patients of *Prameha*




Table 7: Gradation of Symptoms

	Symptoms		
	Daurbalya	Kshudhavriddhi	
0	No weakness in any sort of work	0	Breakfast in morning along with lunch and dinner
1	Weakness in routine work but able to cope with it	1	Twice heavy breakfast along with lunch and dinner
2	Weakness enough to hamper his routine work	2	Heavy breakfast 2 times daily along with lunch and dinner
3	Weakness in slight work or at rest so as to him		
	Kshudhamandya	Ayasen -swasha kashtata	
0	Normal appetite	0	No Swasha kashtata
1	Eats less as apart of routine, reduced desire.	1	Swasha kashtata after climbing 5 floors

	Prerna R Masatkar. Effect of Madhumeha	Nashini Gutika in Sthula l	Prameha wrt Type II Diabetes Mellitus
2	No desire, intake is moderate	2	Swasha kashtata after climbing 2 floors
3	No desire for food and intake is very poor	3	Swasha kashtata after climbing 5-6 steps
	Nakta-Mutrata	Prabhut mutrata	
0	No noctumnal urination	0	Passes urine 4-5 times in whole day
1	1 to 2 times passing urine in the night	1	Passes urine 7-9 times in whole day
2	2to 3 times passing urine in the night	2	Passes urine 10-12times in whole day
3	More than 4 times in	3	Passes urine more than 12 times in whole day
	Pindikodveshtana	Swedati pravrithi	
0	No complaints	0	Sweda after heavy work
1	Pindikodveshtana after 1 hour walk	1	Sweda after 1/2 hour work
2	Pindikodveshtana after 1/2 hour walk	2	Sweda after 15 minute work
3	Pindikodveshtana after 10 minute walk	3	Sweda after 5 minute work
	Hust - padatala daha	Pipasa-atipravrutti	
0	No Daha	0	Feeling of thirst (7-9times/24h) and relieved by drinking water
1	Padatala daha	1	Feeling of moderate thirst (>9-11times/ 24h) and relieved by drinking water
2	Hastpadatala daha sleep not disturb	2	Feeling of excess thirst (>11-13times/ 24h) not relieved by drinking water
3	Hasta padatala daha sleep disturb	3	Feeling of severe thirst (>13times/24h) not relieved by drinking water

Figure 2: Showing Effect of Therapy on Symptom Score of 40 Patients of Prameha




Table 8: Showing Effect of Therapy on Blood Sugar Level of 40 Patients of Prameha

S.	S. Crow		Mean ± SD		Diff of	Cad		D
No.		Group	ВТ	AT	mean ± SD	Sed	ι	Р
1	DCI E	Treated	157.2±48.91	141.4±51.26	15.8±34.78	7. 77	2. 0334	>0.05
1	BSL-F	Control	168.3±53.49	127.8±43.69	37.85±42.15	9. 43	4. 0138	<0.001
2	BSL-PP	Treated	242.5±63.12	224.05±68.40	18.45±53.05	11.86	1. 5556	>0. 1

IJRAPS, 2023:7(6):14-23

		Control	272.45±76.35	209.35±53.30	63.1±73.19	16. 36	3. 8569	<0.01
3	ABGL-	Treated	196.89±55.64	170.38±71.22	26.44±65.42	14. 63	1. 80	>0. 05
3	Random	Control	243±60.85	207.02±58.91	35.97±69.09	15. 45	2. 3286	<0.05
4	HbAlC	Treated	8.58±1.66	7.77±2.06	0.81±1.82	0. 40	2. 025	>0. 05
4	HUAIC	Control	8.84±1.58	7.82±1.83	1.02±1.57	0. 35	2. 9142	<0.01
5	USL	Treated	1.1±1.6	0.50±0.88	0. 6±1. 46	0. 32	1. 87	>0. 5
		Control	1.6±1.54	0.4±0.75	1. 2±1. 196	0. 27	4. 4444	<0.001

Effect of Therapy on Blood Sugar Level: All the patients of this study were explained to measure blood sugar levels before and after the treatment. In treated group *Madhumeha Nashini Gutika* lowered down fasting blood sugar level within the group but when tested by paired 't' test, between two groups where t was 2.0334, p>0.05, suggested that *Madhumeha Nashini Gutika* didn't satisfactorily lowered fasting blood sugar level. But in control group metformin lowered fasting glucose level significantly as p<0.001 (table-8). In the same manner post prandial blood sugar level and average blood sugar level was not significantly reduced in treatment group so as in control group metformin showed highly significant results. **Effect of therapy on HbA1c**: After completion of treatment reduction in HbA1c units was insignificant (t=2.025, p>0.05) in trail group relative to control group where t=2.9142, p<0.01.

Table 9: Showing Effect of Therapy on Weight and BMI of 40 Patients of Prameha

S. No	Character	Group	Mean ± SD		Diff of mean ±SD	SEd	T	P
			ВТ	AT				
1	Weight	Treated	64.15±7.21	62.45±7.30	1.7±0.97	0. 27	8.09	< 0.001
	Control	67.65±4.29	67.7±4.53	-0.05±0.89	0. 198	0.2525	>0.1	
2	DMI	Treated	27.23±2.54	26.70±2.61	0.53±0.30	0.06	8.83	< 0.001
2	BMI	Control	26.85±1.66	26.8305±1.47	0.0195±0.54	0. 12	0.1625	>0.1

Table 10: Table showing Ingredients of Madhumeha Nashini Gutika

S. No.	Name	Proportion	
1	Trivanga Bhasma	1	
2	Gudamara	3	
3	Nimba	3	
4	Shilajatu	6	

Table 11: Table showing the Guna, Rasa, Virya, Vipaka and Doshaghnata of Madhumeha Nashini Gutika

S.No.	Name	Proportion	Guna	Rasa	Virya	Vipaka	Doshaghnata
1	Vanga	1	Laghu Sara, Ruksha	Tikta Kashaya Lavana	Sita	Katu	Vatanashaka Kaphahara
2	Naga	1	Laghu	Tikta	Ushna	Katu	Vatanashaka Kaphahara
3	Yashada	1	Laghu Sukshma	Tikta	Sita	Katu	Vata Kaphahara
4	Gudamara	3	Laghu Ruksha	Kashaya Tikta	Ushna	Katu	Kaphahara Vatahara
5	Nimba	3	Laghu	Tikta Kashaya	Shita	Katu	Kapha Shamaka Pitta Shamaka
6	Shilajatu	6	Sara	Tikta Katu Kashaya	Ushna	Katu	Kapha hara Medohara


DISCUSSION

Ayurvedic physician has described *Pramehi* patients as Sthula and Krisha, in which treatment has to be given. Sthula Pramehi has to be treated with *Apatarpan* which include Samshodhana Samshamana. The drug Madhumeha Nashini Gutika has 100% *Medohara* property. Effect of therapy was observed on the symptoms of *Prameha* as shown in figure no-2. Overall % of relief in treated group was 73.61% which was more than control group where it was found to be 58.59%. More % of relief in symptom score of treated group as compared to control group might be due to properties of Madhumeha Nashini Gutika. Katu and Tikta rasa might be enhancing status of Medodhatvagni because of which Bahuabadhdha Meda might get digested in another form of metabolite. Thus responsible Abadhdha Meda when get reduced symptoms of Madhumeha also get alleviated. As well as it might be alleviating Sharir Shaithilva and might be useful for normal production of Dhatu. As shown in table-9, the difference noted was highly significant in treatment group as "t" was 8.09, p<0.001, while in control group the difference noted was insignificant as "t"=0.2525, p>0.1 (with respect to weight of patients before and after treatment in both the groups). In Sthula Pramehi patient's derangement of *Meda dhatu* is there which causes *Sharir Shaithilya* which can be assessed by BMI. In the present study patients with BMI more than 25 are selected. Results as mentioned earlier of this study indicated that *Madumeha Nashini Gutika* reduced weight and BMI. Above discussion revealed that the drug definitely had beneficial effect on *Bahudrava Shleshma* and *Bahu Abadhdha Meda* in *Sthula Pramehi*. However reduction in blood sugar level in trail group was insignificant which can be augmented by prescribing *Madhumeha Nashini Gutika* along with strict vigilled diet and exercise regimen.

Proposed Mechanism of Action of Madhumeha Nashini Gutika

All the components of this drug have Laghu, Ruksha properties exactly opposite that of Kapha dosha and Meda dhatu. As described in Ayurvedic text, Shilajitu is Pramehaghna and Rasayana drug. Trivanga bhasma is also Mehanashak and removes Dhatu Shaithilya and responsible for Uttam dhatu nirmiti. Gudamara and Nimba have also Khapha Medonashak property.







Ingredients of Madhumeha Nashini Gutika

Finger Print Profile of Madhumeha Nashini Gutika

CONCLUSION

Most of the patients from both the groups were from *Praudhavastha* age group. 47.5% patients were male and 52.5% patients were females. In this study most of the patients belonged to Hindu religion, few were from Muslim community. Maximum numbers of

patients were from middle class and were educated. Most of the patients were indulged in taking *Madhura* and *Lavana rasa* in their diet. Most of the patients had some sort of *Vyasana*. 65% of patients were indulged in sedentary type of work, while maximum number of

patient had habit of idle sitting, Diwa Swap, Ati-Nidra and *Alasya*. (Table 1, 2, 3, 4, 5) 47.5% patients were of Kapha-Vataja prakriti. (Table-6) Most of the patients were having Sthula Akruti and Anup Desha. *Kapha dosha* was dominant in all patients and *Dushti* of Ras, Rakta, Mamsa, Medo, Dhatu was also observed in all patient (Figure-1). It was observed that overall % of relief was more in treated group (73.65%) than control group (58.59%) symptom score (Figure-2). Table-9, showed statistically significant reductions in the wt and BMI of patients in trail group relative to control group. So we came at conclusion that Tikta rasatmak Katu Vipaki Laghu, Ruksha, Sara, Gunatmak and having Kapha Medohara properties Madhemeha Nashini Gutika might be working on Bahu-Drava Shleshma and Bahu-Abadha Meda dhatu. Both the drugs do not have significant effect on renal and liver function and no significant adverse effects were reported.

Future Prospects: To have better results on lowering blood sugar level one must adopt holistic approach while prescribing *Madhumeha Nashini Gutika*, it may work on sugar level when prescribed in higher doses and for longer duration of periods. *Madhumeha Nashini Gutika* may be given as add on therapy in future for better results.

REFERENCES

- 1. Atharvveda 1/3/4
- 2. Sharma R K and Vaidya Bhagawan Das edited Charaka Samhita volume III; Chikitsa sthana 6/4; Chaukhamba Sanskrit Series office, Varanasi reprint edition 2018. pg no 298
- 3. Shashtri Sudarshan edited Madhav Nidan of Shri Madhavkara; vidyotini Hindi commentary and notes; part II chapter 33 Chaukhambha Prakashan, Varanasi reprint edition 2014. pg no1.
- 4. K R Shrikanth Murthi. Ashtang Hridayam vol II Nidan Sthana10/7; Krishndas Academy, Varanasi, 1st edition 1992. pg no 93.
- 5. Sharma R K and Vaidya Bhagawan Das edited Charaka Samhita volume II; Nidan sthana 4/46; Chaukhamba Sanskrit Series office, Varanasi reprint edition 2018. pg no 64.
- 6. K R Shrikanth Murthi. Ashtang Hridayam vol II Nidan Sthana10/20; Krishndas Academy, Varanasi, 1st edition 1992. pg no 95.
- 7. Dr. Sharma A. R. Sushrut Samhita edited, with Sushrutvimarshini Hindi commentary; vol II Chikitsa Sthana11/3, Chaukhambha Surbharti Prakashan; 1st edition 2001. pg no 267.
- 8. Sharma R K and Vaidya Bhagawan Das. edited Charaka Samhita volume II; based on Chakrapanidatta's Ayurved Dipika; Nidan sthana 4/4; Chaukhamba Sanskrit Series office, Varanasi, reprint edition 2018. pg no 53.

- 9. Sharma R K and Vaidya Bhagawan Das. edited Charaka Samhita volume II; based on Chakrapanidatta's Ayurved Dipika; Nidansthana 4/6; Chaukhamba Sanskrit Series office, Varanasi reprint edition 2018. pg no 54.
- 10. Sharma R K and Vaidya Bhagawan Das. edited Charaka Samhita volume III; based on Chakrapanidatta's Ayurved Dipika; Chikitsa sthana 6/4; Chaukhamba Sanskrit Series office, Varanasi reprint edition 2018. pg no 293.
- 11. Dr. Sharma A. R. Sushrut Samhita edited with Sushrutvimarshini Hindi commentary; vol II Chikitsa Sthana 11/3, Chaukhambha Surbharti Prakashan; 1st edition 2001. pg no 267.
- 12. Sharma R K and Vaidya Bhagawan Das edited Charaka Samhita volume II; based on Chakrapanidatta's Ayurved Dipika; Nidan sthana 4/5-8 Chaukhamba Sanskrit Series office, Varanasi reprint edition 2018. pg no 54-56.
- 13. Dr. Sharma R. K. and Vaidya Bhagawan Das edited Charaka Samhita volume III; based on Chakrapanidatta's Ayurved Dipika; Chikitsa sthana 6/57 Chaukhamba Sanskrit Series office, Varanasi; reprint edition 2018. pg no 315.
- 14. Dr. Sharma A. R. Sushrut Samhita edited with Sushrutvimarshini Hindi commentary; vol I Nidana Sthana 6/27, Chaukhambha Surbharti Prakashan; 1st edition 2001. pg no 508.
- 15. Dr. Sharma R. K. and Vaidya Bhagawan Das edited Charaka Samhita volume III; based on Chakrapanidatta's Ayurved Dipika; Chikitsa sthana 6/56; Chaukhamba Sanskrit Series office, Varanasi; reprint edition 2018. pg no 314.
- 16. Dr. SharmaA. R. Sushrut Samhita edited with Sushrutvimarshini Hindi commentary; vol I Nidana Sthana 6/24, Chaukhambha Surbharti Prakashan; 1st edition 2001; pg no 507.
- 17. Dr. Sharma R. K. and Vaidya Bhagawan Das edited Charaka Samhita volume III; based on Chakrapanidatta's Ayurved Dipika; Chikitsa sthana6/15; Chaukhamba Sanskrit Series office, Varanasi; reprint edition 2018. pg no 303.
- 18. Shri Pandit Vaidya L. edited Ashtang Samgraha with Sarvang Sundari Vyakhya Chikitsa Sthana 14/3; Shri Baidyanath Ayurved Bhawan pvt. lt.; Nagpur; 1st edition 1989. pg. no. 838.
- 19. Sharma R. K. and Vaidya Bhagawan Das edited Charaka Samhita volume III; based on Chakrapanidatta's Ayurved Dipika; Chikitsa sthana 6/16; Chaukhamba Sanskrit Series office, Varanasi; reprint edition 2018. pg. no 303.
- 20. Shri Pandit Vaidya L. edited Ashtang Samgraha with Sarvang Sundari Vyakhya; Chikitsa Sthana 14/51, Shri Baidyanath Ayurved Bhawan pvt. ltd Nagpur; 1st edition 1989. pg. no. 848.

Prerna R Masatkar. Effect of Madhumeha Nashini Gutika in Sthula Prameha wrt Type II Diabetes Mellitus

- 21. Sharma R. K. and Vaidya Bhagawan Das edited Charaka Samhita volume I; based on Chakrapanidatta's Atyrved Dipika; Sutra
- sthana1/51; Chaukhamba Sanskrit Series office, Varanasi; reprint edition 2018. pg no 37.
- 22. Acharya Yadavji Trikamji, Rasamrutam Adhyaya 9/125-12

Cite this article as:

Prerna R Masatkar, Raman R Ghungralekar. A Controlled Evaluation of Effect of Madhumeha Nashini Gutika in Sthula Prameha with reference to Type II Diabetes Mellitus. International Journal of Research in AYUSH and Pharmaceutical Sciences, 2023;7(6):14-23.

https://doi.org/10.47070/ijraps.v7i6.146

upport: Nil, Conflict of interest: None Declared

*Address for correspondence Dr. Prerna R Masatkar,

Associate Professor, Department of Kayachikitsa, Government Ayurved College, Nagpur, Maharashtra. Email:

prernamasatkar29@gmail.com Mob. no. 9834707734

Disclaimer: IJRAPS is solely owned by Mahadev Publications - A non-profit publications, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IJRAPS cannot accept any responsibility or liability for the articles content which are published. The views expressed in articles by our contributing authors are not necessarily those of IJRAPS editor or editorial board members.